touchNEUROLOGY caught up with the INS President, Prof. Marc Russo, to discuss the upcoming congress and what to expect. The International Neuromodulation Society (INS) is excited to announce the relaunch of the in-person INS 15th World Congress in Barcelona, Spain, May 21-26, 2022. The event will continue to maintain an online presence, providing opportunities for virtual access to the educational content.
The congress subtitled “Neuromodulation: From Scientific Theory to Revolutionary Therapy”, hopes to emphasize that neuromodulation therapies from deep brain stimulation for movement disorders, epilepsy and psychiatric disorders, to spinal cord stimulation for chronic pain and locomotion, to sacral nerve stimulation for urinary and fecal incontinence have all developed from rigorous scientific theory and have matured into proven clinical therapies.
The International Neuromodulation Society (INS) is a non-profit group of clinicians, scientists and engineers dedicated to the scientific development and awareness of neuromodulation – the alteration of nerve activity through the delivery of electrical stimulation or chemical agents to targeted sites of the body. The INS also provides information for patients and produces rolling news briefs about this rapidly evolving field.
- Could you tell us a little about the upcoming INS congress? (0:06)
- What are the main objectives of the INS? (1:28)
- What research topics can attendees expect at the upcoming congress? (2:33)
Disclosures: Marc Russo has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
View more INS content here
Share this Video
Related Videos In Psychiatric Disorders
Treatment algorithm for managing treatment-resistant depression: Charles Nemeroff, APA 2023
Guidance following the failure of monotherapy when treating depression is limited, as such clinicians usually take a trial and error approach to treatment, a treatment algorithm could help personalise patient care and achieve improved outcomes. It was a pleasure to talk with Dr. Charles Nemeroff (The University of Texas at Austin, Dell Medical School, Austin, […]
Major depression treatment landscape, unmet needs and emerging therapeutics: Charles Nemeroff, APA 2023
Despite being one of the most common serious psychiatric disorders, major depression remains difficult to treat with only 30-50% of patients achieving remission from monotherapy or talk therapy, however many promising new antidepressants are currently under investigation. We were delighted to talk with Dr. Charles Nemeroff (The University of Texas at Austin, Dell Medical School, […]
Barriers when implementing positive psychiatry interventions: Erick Messias, APA 2023
Implementing positive psychiatry approaches can face various barriers across different levels of care. These include resistance to change, limited resources, time constraints, and the dominance of a deficit-focused model. In this touchNEUROLOGY interview, we speak with Dr Erick Messias (Saint Louis University School of Medicine, St. Louis, MO, USA) to discuss how to address these […]